摘要
目的观察瑞舒伐他汀联合双环醇治疗非酒精性脂肪性肝炎(NASH)的临床疗效。方法选取2020年8月—2021年8月福建省立医院收治的NASH患者92例,按照随机分组原则分为对照组(n=46)与观察组(n=46)。对照组给予瑞舒伐他汀治疗,观察组在对照组基础上联合双环醇治疗。2组均治疗24周。比较2组临床疗效,治疗前、治疗24周后血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、肝功能指标[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GGT)]、肝纤维化指标(肝脏胶原Ⅰ、胶原Ⅳ、纤维粘连蛋白、胶原ⅠmRNA、胶原ⅣmRNA、纤维粘连蛋白mRNA),不良反应。结果观察组治疗总有效率为97.83%,高于对照组的82.61%(χ^(2)=4.434,P=0.035)。治疗24周后,2组TC、TG、LDL-C水平低于治疗前,且观察组低于对照组(P<0.05);2组治疗前及治疗24周后HDL-C水平比较,差异无统计学意义(P>0.05)。治疗24周后,2组ALT、AST、GGT水平低于治疗前,且观察组低于对照组(P<0.05)。治疗24周后,2组肝脏胶原Ⅰ、胶原Ⅳ、纤维粘连蛋白、胶原ⅠmRNA、胶原ⅣmRNA、纤维粘连蛋白mRNA低于治疗前,且观察组低于对照组(P<0.05)。观察组不良反应总发生率为4.35%,低于对照组的17.39%(χ^(2)=4.039,P=0.044)。结论瑞舒伐他汀联合双环醇治疗NASH的临床疗效确切,可有效改善肝功能,抑制肝纤维化,调节血脂,且安全性较高。
Objective To observe the clinical efficacy of rosuvastatin combined with bicyclol in the treatment of no-nalcoholic steatohepatitis(NASH).Methods A total of 92 cases of patients with NASH were selected from August 2020 to August 2021 in Fujian Provincial Hospital,which were divided into control group(n=46)and observation group(n=46)according to the principle of random grouping.The control group was treated with rosuvastatin,and the observation group was treated with bicyclol on the basis of the control group.Both groups were treated for 24 weeks.Clinical efficacy,blood lipid indexes(TC,TG,HDL-C,LDL-C),liver function indexes(ALT,AST,GGT),liver fibrosis indexes(liver collagenⅠ,collagenⅣ,fibronectin,collagenⅠmRNA,collagenⅣmRNA,fibronectin mRNA)before treatment and 24 weeks after treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of the observation group was 97.83%,which was higher than 82.61%of the control group(χ^(2)=4.434,P=0.035).After 24 weeks of treatment,the levels of TC,TG and LDL-C in the two groups were lower than those before treatment,and those in the observation group were lower than control group(P<0.05);there was no significant difference in HDL-C levels between the two groups before and after 24 weeks of treatment(P>0.05).After 24 weeks of treatment,the levels of ALT,AST and GGT in the two groups were lower than thosebefore treatment,and those in the observation group were lower than control group(P<0.05).After 24 weeks of treatment,the liver collagenⅠ,collagenⅣ,fibronectin,collagenⅠmRNA,collagenⅣmRNA and fibronectin mRNA in the two groups were lower than those before treatment,and those in the observation group were lower than that control group(P<0.05).The total incidence of adverse reactions in the observation group was 4.35%,which was lower than 17.39%in the control group(χ^(2)=4.039,P=0.044).Conclusion Rosuvastatin combined with bicyclol have an exact clinical effect for NASH,which can effectively improve liver function and inhibit liver fibrosis,regulate blood lipid,and with high safety.
作者
梁琼
庄捷
刘江建
LIANG Qiong;ZHUANG Jie;LIU Jiangjian(Department of Pharmacy,Fujian Provincial Hospital,Fuzhou 350001,China)
出处
《临床合理用药杂志》
2022年第36期23-26,共4页
Chinese Journal of Clinical Rational Drug Use
